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Shared decision-making regarding adjuvant systemic therapy in breast cancer is
based on both properly conveying information about the prognosis of the disease
and the benefits and risks of adjuvant treatment, as well as the patient’s ability
to understand this information. This work proposed to analyze oncologists’ and
patients’ perceptions of the risk of recurrence with and without chemotherapy and
toxicity, and the factors influencing said impressions. This was a prospective, cross-
sectional, multicenter study that involved 281 breast cancer patients and 23 oncologists.
Prognosis (risk of recurrence with and without chemotherapy and risk of severe
toxicity with chemotherapy) and shared decision making (SDM) questionnaires were
completed by all participants; breast cancer patients also filled out the 18-item Brief
Symptom Inventory (BSI-18). Oncologists’ prediction of risk of relapse without and with
chemotherapy (30.4 and 13.3%) and risk of severe toxicity (9.8%) were more optimistic
than those of breast cancer patients (78.6, 29.6, and 61%, respectively). The greater
the severity, the higher the risk of relapse according to the oncologists (p = 0.001); not
so for the patients. Older physicians and more experienced ones predicted lower risk of
relapse with and without chemotherapy and less severe toxicity than younger doctors
and those with less experience (p < 0.001). Oncologists’ SDM and their prediction of
risk of relapsing with chemotherapy correlated negatively with patients’ SDM and their
prediction of risk of severe toxicity (p < 0.01). There is a positive correlation between
psychological distress (BSI-18) and prognosis of risk of recurrence with chemotherapy
in breast cancer patients (p < 0.001). These results stress the importance of improving
doctor–patient communication in SDM. In breast cancer patients undergoing treatment
with curative intent, expectations of being cured would increase and treatment-related
anxiety would decrease by enhancing doctor–patient communication to coincide more
with respect to risk of relapse and toxicity, thereby enhancing patients’ quality of life.
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INTRODUCTION
Breast cancer is the second most common cancer overall and
the leading cancer in women, with more than two million
new cases diagnosed in 2018 (Fitzmaurice et al., 2018). Surgery
is the treatment of choice for non-advanced breast cancer;
chemotherapy, radiotherapy, and hormone therapy are adjuvants
with consolidated benefit in diminishing the risk of relapse
and improving long-term survival (Waks and Winer, 2019).
These treatments provoke fear surrounding side effects such as
alopecia, body changes, pain, fatigue. . . (Dooley et al., 2017)
that add to their fear of recurrence (Miroševič et al., 2019).
In recent years, other factors, such as tumor grade, estrogen
receptor, and progesterone receptor status, HER2 overexpression,
and, in some cases, genomic profiles, have been added to
the prognostic value of TNM staging based on tumor size
(T), number of regional lymph nodes affected (N), and the
presence or absence of distant metastases (M), yielding more
robust and precise prognostic information (Schönherr et al.,
2012; Piñeros et al., 2019). Physicians estimate risk of adjuvant
treatment-associated toxicity on the rates of side effects reported
in clinical trials. Nevertheless, these trials are conducted in
a highly selected population; thus, their data can scarcely be
extrapolated to clinical practice where patients are more fragile
and older and present more comorbidities, all of which can
modify patients’ risk of toxicity (Schönherr et al., 2012; Piñeros
et al., 2019). Knowing the prognosis of the disease and risk
of adjuvant treatment-related toxicity is relevant to doctor–
patient shared decision making (SDM) and tailoring treatment
to risk, as well as helping the patient to cope better and
lessening psychological distress (Lobb et al., 2001). Nevertheless,
little is known about the effectiveness of communicating this
kind of information in the oncologist’s office in a situation
in which the effect of recent cancer surgery and emotional
stress affect the ability to comprehend the language being used,
thereby casting doubt on the validity of this SDM between
patient and oncologist as to the advisability of receiving adjuvant
treatment, its benefits, and risks. Furthermore, several factors
influence how the patient participates in SDM (Street et al.,
1995; Bakker et al., 2001; Janz et al., 2004; Maly et al.,
2004; Ingersoll et al., 2019). Low-educated and older patients
are often associated with a passive role (Street et al., 1995),
with education being more consistent than age as a factor
impinging on patient–physician communication (Janz et al.,
2004). Additionally, doctors may provide less informative to
individuals with lower levels of education (high school or
less) and lower incomes (Bakker et al., 2001). As for race,
fewer consultations for information concerning prognosis have
been reported in the black and Latino populations, as well as
unrealistic optimism regarding this prognosis (Ingersoll et al.,
2019). In North American studies, ethnic minority women
(i.e., African American and Latino breast cancer patients) were
considerably less likely than white patients to perceive themselves
as the chief treatment decision-makers, while at the same time,
they were more likely to question their physician about their
treatment, possibly due to mistrust of the healthcare system
(Maly et al., 2004).
Most of the literature comparing doctors’ and patients’
expectations is founded on research in more advanced stages of
the disease, concluding that patients tend to be more optimistic
than doctors (Robinson et al., 2008; Gramling et al., 2016;
Malhotra et al., 2019). Few publications address this issue in
early-stage breast cancer (Siminoff et al., 1989; Ravdin et al.,
1998). The few studies found reveal that agreement between
patients and oncologists regarding the benefits and risks involved
with adjuvancy is poor (Siminoff et al., 1989) and that patients
are apt to overestimate the curative value of adjuvant therapy
in 70–80% of the cases with respect to non-treatment (Ravdin
et al., 1998). The optimistic confidence in treatment may reflect
trouble in physician–patient communication (Mackillop et al.,
1988), the influence of other sources of information (Adamson
et al., 2019), or patients’ minimizing or denying that cancer can
be life-threatening (Mackillop et al., 1988; Wakiuchi et al., 2019).
Coincidence between patients and oncologists in estimating
risk of disease relapse and chemotherapy-associated toxicity is
important to reduce confusion, adjust patients’ expectations,
boost treatment compliance and involvement in SDM, and
plan medical care and healthcare services that patients may
need, thereby improving their quality of life (Lobb et al.,
1999). So far as we know, in the setting of resected, non-
metastatic breast cancer, there are no recent studies that examine
doctor–patient coincidence with respect to the estimation of
relapse with/without adjuvant chemotherapy and regarding the
risk of treatment toxicity, which is the main objective of our
study. Secondarily, we seek to explore the sociodemographic
and psychological factors associated with estimating risk of
recurrence and toxicity. We postulate that oncologists will
be more realistic in their estimations of these two situations
than patients and that the greater the patient-perceived




This is a prospective, cross-sectional, multicenter study involving
oncologists and non-metastatic breast cancer patients from all
over Spain. Inclusion criteria were as follows: >18 years of age;
histologically confirmed, non-advanced, resected solid tumor;
eligible for adjuvant treatment. Exclusion criteria consisted of
adjuvant treatment with hormone therapy alone and patients
with dementia or any other serious mental illness that, in
the investigator’s opinion, impeded survey comprehension or
hampered the patient’s ability to participate in the study. Of the
310 breast cancer patients screened, 29 were ineligible (5 failed to
meet inclusion criteria, 9 met an exclusion criterion, and 15 had
incomplete data).
Ethics Statements
The study was approved by the Research Ethics Committee
of the Principality of Asturias (January 19, 2015) and by the
Spanish Agency of Medicines and Medical Devices (AEMPS)
(April 4, 2015). All participants signed an informed consent
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TABLE 1 | Prognostic predictions about risk of relapse and toxicity.
Variables M (SD) Very low Low High Very high
Oncologists’ prediction 0–25% 26–50% 51–75% 76–100%
Risk of relapse without
chemotherapy
30.4 (16.2) 43.4 45.3 10.1 1.1
Risk of relapse with
chemotherapy
13.3 (8.4) 91.4 8.6 – –
Risk of severe toxicity 9.8 (7.4) 96.6 3.4 – –
Breast cancer patients’
prediction
Risk of relapse without
chemotherapy
78.6 (20.4) 1.7 19.1 40.2 39.0
Risk of relapse with
chemotherapy
29.6 (20.4) 72.5 22.9 2.1 2.5
Risk of severe toxicity 61.0 (22.8) 14.2 40.0 32.5 13.3
Bold, p < 0.05.
form prior to participation. Participation was voluntary and
anonymous and would not affect patient care. Subjects completed
questionnaires following their first appointment with the
oncologist, approximately 1 month after surgery. The physician
had informed them of the risk of relapse with and without
treatment suited to their stage of cancer, risk factors, molecular
subtype, and possible side effects of chemotherapy. Data were
collected and updated by medical oncologist, specifically trained
to meet the study requirements, through a web-based platform.1
Data and Questionnaires
Sociodemographic and clinical data were collected during the
first visit to the medical oncology department during which
the advisability of receiving adjuvant treatment was discussed.
Oncologists had to indicate their age and years of experience,
and both clinicians and patients had to predict risk of relapse
with and without chemotherapy and the risk of toxicity
using a 0- to 100-point numerical rating scale. Participants
completed questionnaires [nine-item Shared Decision Making
Questionnaire (SDM-Q-9) and 18-item Brief Symptom Inventory
(BSI-18)] at home between the first visit and the start of adjuvant
1www.neocoping.es
chemotherapy and oncologists filled in the SDM-Q-Doc after the
first consultation.
Doctors had to answer the SDM Questionnaire-Physician’s
version (SDM-Q-Doc) (Scholl et al., 2012) to express their
perspective on SDM and how well they followed it with their
patients. The questionnaire consists of nine items, each of which
describes one step of the SDM process; it was adapted and
subsequently validated with good internal consistency in Spain
(α = 0.90) (Calderon et al., 2017). Clinicians had to rate each item
on a five-point Likert scale, yielding a summary score from 0 to
36; the higher the score, the greater the physician’s satisfaction
with the information provided.
Participants completed the SDM Questionnaire–Patient’s
Version (SDM-Q-9). This questionnaire was published by
Kriston et al. (2010), adapted to Spanish, and has proven good
internal consistency in Spain (α = 0.90) (Calderon et al., 2018).
It consists of nine items, each portraying one step of the
SDM process (Kriston et al., 2010), and is appraised on a
five-point Likert scale with a summary score of 0–36; the
higher the score, the greater the patient’s satisfaction with the
information received.
Patients also answered the BSI-18 (Derogatis, 1993) that
contains 18 items assessing somatization, depression, and
anxiety. Respondents were asked to answer based on how they
had felt over the previous 7 days; each item was rated on a
five-point Likert scale. Participants whose T-score was ≥67,
as per cutoff values recommended by Derogatis (1993), were
deemed “probable anxiety or depression.” The higher the score,
the greater the psychological distress in the previous month.
α coefficients ranged between 0.75 and 0.88 in Spain sample
(Calderon et al., 2020).
Statistical Methods
We used descriptive statistics for breast cancer patients’ clinical
data, as well as for participants’ and oncologists’ demographic
information. T-test was used for quantitative variables and
χ2 test for qualitative variables to appraise the degree of
contrast between prognosis and toxicity estimations made
by patients and oncologists. We used analyses of variance
to assess variations in doctors’ and patients’ estimation by
stage and age; Pearson correlation coefficients analyzed the
TABLE 2 | Prognostic predictions about risk of relapse and toxicity by stage.
Variables Stage IB Stage II Stage III F p Effect size η2
M (SD) M (SD) M (SD)
Oncologists’ prediction
Risk of relapse without chemotherapy 25.8 (13.1) 31.7 (17.1) 42.0 (15.2) 11.529 0.001 0.080
Risk of relapse with chemotherapy 10.3 (5.7) 13.6 (8.4) 23.9 (9.5) 30.852 0.001 0.189
Risk of severe toxicity 9.1 (5.5) 10.2 (9.0) 9.9 (3.5) 0.778 0.460 –
Breast cancer patients’ prediction
Risk of relapse without chemotherapy 72.4 (21.0) 81.8 (19.5) 86.9 (16.6) 7.958 0.001 0.063
Risk of relapse with chemotherapy 29.1 (20.9) 28.4 (19.7) 38.0 (21.1) 2.224 0.110 –
Risk of severe toxicity 58.5 (22.0) 61.9 (22.5) 65.2 (22.8) 1.000 0.369 –
Bold, p < 0.05.
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TABLE 3 | Correlations between prognostic prediction and sociodemographic variables.
Oncologists’ prediction Breast cancer patients’ prediction
Variables Relapse without chemo Relapse with chemo Toxicity Relapse without chemo Relapse with chemo Toxicity
Oncologists’ age −0.267** −0.273** −0.213** 0.076 −0.088 −0.013
Years of experience −0.256** −0.256** −0.188** 0.064 −0.083 −0.012
Patient’s age −0.011 −0.054 −0.070 0.101 0.099 −0.022
SDM Oncologist −0.079 −0.160* −0.029 – – –
SDM patient – – – 0.035 −0.054 −0.228*
BSI psychological distress – – – 0.026 0.206** 0.096
*p < 0.01; **p < 0.001.
relationships between estimations and demographic variables,
SDM, and psychological distress. Given the large study sample
size, the F ratio could incorrectly detect statistically significant
differences. We therefore included the effect size (η2) using
the classic formula proposed by Fisher (1928) to adjust effect
estimate, avoiding bias sample. The interpretation of effect
size is straightforward: values <0.20 indicate a very small or
insignificant magnitude of effect; 0.20–0.49, a small effect size;
0.50–0.79, a moderate effect size; and values >0.80 indicate a
large effect size. We set a statistical significance level of 0.05.
Statistics were performed using the IBM SPSS software package
for Windows, version 23.0 (SPSS, Inc., Chicago, IL).
RESULTS
Participants’ Characteristics
The physicians’ sample comprised 23 medical oncologists (5
males and 13 females) employed at 11 Spanish hospitals. They
have a mean age of 36.3 years (SD = 8.1, range = 28–59 years)
and 12.9 years (SD = 9.8, range = 4–38 years) of experience,
respectively. Sixty-five percent are super-specialists, and 56.5%
work at a public university hospital.
The breast cancer patient sample consisted of 281 subjects.
Cancers were stage IB (38.4%), II (52.3%), or III (9.3%).
All subjects had undergone curative surgery in the previous
month (53.5% partial resection vs. 46.5 complete resection)
and were treated with adjuvant chemotherapy (64.2%
conventional and 35.8% modified treatment), and 66.4%
received sequential radiotherapy.
Mean age was 53.2 years (SD = 10.8, range = 26–77); 72%
were married or partnered; 77.8% had primary or secondary
education, and 44.4% were retired.
Estimation of Risk of Recurrence and
Toxicity
Oncologists’ prognosis of risk of breast cancer relapse without
chemotherapy was 30.4% (45.3% deemed risk to be low), while
the estimated risk of recurrence with chemotherapy-related
chemotherapy was 13.3% (91.4% calculated that it would be very
low). The risk of severe toxicity was estimated to be 9.8% (96.6%
of the oncologists thought it was very low) (see Table 1).
Breast cancer patients’ prediction of risk of recurrence without
chemotherapy was 78.6% (40.2% felt it was high), while they
estimated a 29.6% risk of relapse with chemotherapy (72.5%
thought it was very low). The estimated risk of suffering severe
toxicity was 61% (40% of patients deemed that it was low).
Oncologists and patients differed significantly in their
prediction of relapse without chemotherapy (χ2 = 15.901,
p = 0.006) and with chemotherapy (χ2 = 9.702, p = 0.021) and in
their estimation of severe toxicity (χ2 = −12.120, p = 0.007). For
all three situations, patients believed they were at higher risk than
did oncologists, overestimating the risk of recurrence with and
without chemotherapy, as well as their risk of severe side effects
if they received chemotherapy.
Estimation of Risk of Recurrence and
Toxicity by Stage
For patients with stages IB, II, and III disease, oncologists’
prognoses regarding risk of relapse without chemotherapy
were 25.8, 31.7, and 42%, respectively. They estimated risk of
recurrence with chemotherapy to be 10.3, 13.6, and 23.9%,
respectively. The risk of severe toxicity with chemotherapy was
believed to be 9.1, 10.2, and 9.9%, respectively (see Table 2).
Patients with breast cancer stages IB, II, and III predicted
their risk of recurrence without chemotherapy to be 72.4, 81.8,
and 86.9%, respectively. They estimated their risk of relapse with
chemotherapy to be 29.1, 28.4, and 38%, respectively, and of
suffering severe toxicity to be 58.5, 61.9, and 65.2%, respectively.
Clinicians predicted risk of relapse differently depending
on tumor stage, estimating greater risk without chemotherapy
(F = 11.529, p = 0.001, η2 = 0.080) and with chemotherapy
(F = 30.852, p = 0.001, η2 = 0.189) for individuals with higher
stages. The same trend was apparent in patients’ prediction of risk
of relapse without chemotherapy by stages (F = 7.958, p = 0.001,
η2 = 0.063). No significant stage-based differences were observed
in patients’ predictions of risk of relapse with chemotherapy or of
severe toxicity.
Factors Modulating Estimated Risk
There is a significant correlation between oncologists’ age and
years of experience and their risk prediction. Young doctors
and those with fewer years of experience prognosticate greater
risk of relapse than older, more veteran physicians both without
chemotherapy (r = −0.267, p < 0.001; r = −0,256, p < 0.001,
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respectively) and with chemotherapy (r = −0.273, p < 0.001;
r = −0.256, p < 0.001, respectively). The same was seen with
respect to risk of severe toxicity (r = −0.213, p < 0.001;
r = −0.188, p < 0.001, respectively). However, participants’ risk
prediction did not correlate with doctors’ age, years of experience,
or patients’ age (see Table 3).
SDM-Q-Doc and Q-9 correlated significantly with some
predictions. The higher the estimated risk of relapse with
chemotherapy, the less satisfied the oncologist was with SDM
(r = −0.160, p < 0.01). Similarly, patients were less satisfied with
SDM when their risk of severe toxicity was higher (r = −0.228,
p < 0.01).
There is a positive, significant correlation between
psychological distress (BSI-18) and patient prognosis of greater
risk of recurrence with chemotherapy (r = 0.206, p < 0.001).
DISCUSSION
Overall, patients’ predictions of risk their cancer recurring
with and without chemotherapy tended to be higher than
oncologists’. Moreover, while physicians estimated greater risk
of relapse as disease stage increased, patients only exhibited
this tendency when they predicted risk of recurrence without
chemotherapy, trusting in their treatment regardless of their
initial medical situation. In general, doctors considered that the
risk of relapse with and without chemotherapy was low and
very low, respectively, whereas patients felt that their risk with
chemotherapy was very low and high without chemotherapy,
respectively. The same trend was observed for risk of toxicity. The
literature points toward oncology patients being more optimistic
than oncologists in the context of advanced cancer (Robinson
et al., 2008); nonetheless, we have only found one study that
examines doctors’ and cancer patients’ perceptions in the early
stages of the disease. An old study reports that while patients
and oncologists coincided insofar as risk of recurrence without
adjuvant treatment is concerned, such was not the case with
adjuvant treatment (60% patients overestimated their possibilities
of being cured with adjuvant treatment by 20% or more vs. their
oncologists) or with respect to treatment-associated risks. These
results, which differ from ours, are not directly comparable, given
that therapies, survival, and physician–patient communication
have changed tremendously over time. Focusing on the patients,
we detected a sizable difference between the perception of risk
of relapse with chemotherapy (high) and without (very low).
Patients’ perception of less risk of relapse with or without
adjuvant treatment is disproportionate and unrealistic in terms
of the expected benefit and is also seen in a classic study, where
expectations of a 79% decrease in the risk of recurrence with
adjuvant chemotherapy were observed (Ravdin et al., 1998). We
believe that three different factors may influence our results: (1)
doctor–patient communication, which we consider should be less
paternalistic and more patient-focused; (2) patients’ knowledge
about cancer; and (3) interpersonal relations with other agents,
notably the media and patient associations.
Several studies refer to the importance of physician–
patient communication (Gramling et al., 2016;
Bos-van den Hoek et al., 2019; Trant et al., 2019). Likewise,
some classic studies have determined that the discrepancy
between doctors’ and patients’ expectations may be due to
physicians failing to provide quantitative data (Siminoff et al.,
1989; Loprinzi et al., 1994). Although doctors are increasingly
furnishing more quantitative data regarding the disease (Belkora
et al., 2009; Zikmund-Fisher et al., 2016), most patients continue
to estimate their risk of recurrence and treatment-associated risk
inaccurately (Belkora et al., 2009). Consequently, variables such
as level of education, psychological status, or patients’ familiarity
with medical concepts may affect their estimations. Similarly,
some authors suggest that it is difficult for patients to understand
the technical and scientific aspects of chemotherapy (Wakiuchi
et al., 2019), which ultimately leads to knowledge based on their
own experience in which aspects such as their vision of the
disease, their relatives’ and acquaintances’ experiences in the
same circumstance, their own coping style, or the confidence they
have in themselves to confront their cancer all take precedence
(Slevin et al., 1990; Wakiuchi et al., 2019; Bos-van den Hoek
et al., 2019). The lack of information concerning the medical
condition and/or treatment is one of the leading causes of
patients’ dissatisfaction (Calderon et al., 2018). In fact, at present,
most want to receive more information, as well as to participate
more in the decision-making process, albeit the proportion of
people who prefer a more active role differs across countries
(Calderon et al., 2018). A survey conducted in eight European
countries revealed that patients wanted to participate in decision
making, although their expectations about their involvement in
healthcare decisions differed significantly across countries; for
example, in Spain, participants preferred a more paternalistic
model than in Switzerland or Germany (Elwyn et al., 2014).
As for cognitive aspects, the fact that they had only learned
of their cancer diagnosis a few weeks earlier may have led
society’s fear of cancer to prevail, as it is generally associated
with death (Wakiuchi et al., 2019), as well as the feeling
that their very survival was at stake (Mackillop et al., 1988).
In our study, we believe that the scenario of tremendous
uncertainty and possible physical discomfort due to recent
surgery and current recovery, together with initiating a new
treatment, may have magnified patients’ estimation of risk of
relapse and toxicity.
Other studies also point to the effect of other sources
of information, such as relatives, cancer survivors, support
groups, non-physician healthcare personnel, and educational
material that could modify patients’ perception of risk of relapse
(Adamson et al., 2019).
Turning our attention to the physician cohort, prediction of
risk of relapse, with and without chemotherapy, and of severe
toxicity was related to oncologists’ age and years of experience.
This is consistent with other studies, where these doctor-related
variables contribute to shaping their prognosis (Taniyama et al.,
2014). On the other hand, they feel that SDM is more difficult
when they perceive a higher risk of relapse. Smith et al. (2013)
report that discussing uncertainty and risks challenges patient–
clinician communication; therefore, when the physician finds
himself/herself in a complex situation, he/she may feel more
uncomfortable with SDM.
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As for patients, those suffering greater psychological distress
predicted higher risk of relapse with chemotherapy. This
reveals a negative, defeatist attitude, without losing sight of
the numerous studies that indicate that depression and anxiety
correlate with a higher risk of mortality in cancer patients
(Shim et al., 2020). This illustrates the need to detect and
support these individuals to relieve their psychological distress,
which will not only affect their quality of life, but may
also improve their prognosis. In contrast, patients who are
more satisfied with SDM estimated a lower risk of severe
toxicity, which may indicate that a good interview bolsters
their confidence in treatment and gives them a greater
perception of safety. Hjerl et al. (2003) found that treatment
side effects influence patients’ acceptance of treatment. As
previously laid out, most patients were willing to accept
intensive chemotherapy for even a slight chance of benefit
(Slevin et al., 1990).
This study’s findings should be considered in conjunction
with its limitations. First, the present study was cross-sectional
in nature; therefore, it was not possible to determine the
directionality of the relationships observed. Future studies
should explore perceptions of risk of relapse and severe
toxicity after adjuvant chemotherapy is completed, with an
end to assessing whether these perceptions are changing
over time and how variables relate to one another. Second,
patients’ and oncologists’ responses have been collected by
means of questionnaires, which, on the one hand, may have
limited the spectrum of answers and, on the other, hindered
delving into personal motivations and comprehension. Third,
the results obtained in this study are specific for patients
who underwent surgery with curative intent for stage I,
II, or III breast cancer, making it difficult to extrapolate
to metastatic disease and other types of cancer given the
specificities of this patient cohort. Fourth, in all cases, the
indication for adjuvant chemotherapy was based on international
clinical guidelines, and all agreed to receive it; consequently,
we do not know to what degree this decision may have
influenced patients’ predictions of their risk of relapse without
chemotherapy, as a variable they may not have deemed
realistic. Finally, it would be advisable to enlarge the sample of
oncologists in the future.
As for the clinical implications of these findings, SDM
about adjuvant treatment and patients’ understanding of cancer
prognosis are complex issues; hence, it may be necessary
to ascertain each individual’s perception and communicate
information over consecutive visits. Furthermore, improving
physician–patient communication in pursuit of more realistic
expectations regarding risk of relapse and toxicity could lessen
anxiety, depression, and fear of treatment, thereby enhancing
patients’ quality of life.
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